Emergent BioSolutions Inc.
EBS
$8.07
-$0.06-0.74%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -23.63% | -21.34% | -44.68% | -26.03% | -29.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -23.63% | -21.34% | -44.68% | -26.03% | -29.61% |
| Cost of Revenue | -23.58% | -23.61% | -74.95% | -35.59% | -42.31% |
| Gross Profit | -23.71% | -19.55% | 192.67% | -15.20% | 13.09% |
| SG&A Expenses | -12.87% | -57.06% | -43.08% | -37.85% | -20.92% |
| Depreciation & Amortization | 0.00% | 0.00% | -0.61% | 0.62% | 0.62% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.04% | -32.11% | -66.07% | -34.08% | -34.44% |
| Operating Income | -58.04% | 6.46% | 100.31% | 26.63% | 66.11% |
| Income Before Tax | -83.70% | -59.55% | 93.77% | 666.12% | 49.36% |
| Income Tax Expenses | 5.41% | -76.81% | -136.09% | 696.77% | 174.00% |
| Earnings from Continuing Operations | -74.44% | -55.40% | 95.76% | 655.56% | 36.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -74.44% | -55.40% | 95.76% | 655.56% | 36.77% |
| EBIT | -58.04% | 6.46% | 100.31% | 26.63% | 66.11% |
| EBITDA | -100.91% | 2.41% | 117.87% | 12.57% | 181.48% |
| EPS Basic | -80.43% | -55.49% | 95.89% | 625.06% | 39.45% |
| Normalized Basic EPS | -42.31% | -28.58% | 90.63% | 673.08% | 40.27% |
| EPS Diluted | -79.75% | -55.83% | 95.89% | 600.00% | 39.22% |
| Normalized Diluted EPS | -42.31% | -29.59% | 90.63% | 633.95% | 40.27% |
| Average Basic Shares Outstanding | -3.32% | 0.19% | 3.04% | 4.21% | 4.43% |
| Average Diluted Shares Outstanding | -3.32% | 1.62% | 3.04% | 9.77% | 4.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |